Latino versus caucasian response to atomoxetine in attention-deficit/ hyperactivity disorder

Journal of Child and Adolescent Psychopharmacology

Volumn 18, Issue 1, 2008, Pages 44-53

  Tamayo, Jorge M ^a,b   Pumariega, Andres ^c,g   Rothe, Eugenio M ^d   Kelsey, Douglas ^e   Allen, Albert J ^e   Vélez Borrás, Jesús ^f   Williams, David ^e   Anderson, Susan G ^e   Durell, Todd M ^e  

^a UNIVERSIDAD CES   (Colombia)

^b UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^c Hospital and Medical Center ^*  (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e ELI LILLY AND COMPANY   (United States)

^f UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^g TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; CYTOCHROME P450 2D6; PLACEBO;

ABDOMINAL PAIN; ADOLESCENT; APPETITE; ARTICLE; ATTENTION DEFICIT DISORDER; CAUCASIAN; CHILD; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIZZINESS; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; ETHNICITY; FEMALE; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTPATIENT CARE; SCORING SYSTEM; SIDE EFFECT; SORE THROAT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; CYTOCHROME P-450 CYP2D6; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HUMANS; MALE; PROPYLAMINES;

EID: 39849092897     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2006.0132     Document Type: Article

References (27)

1. th edition (DSM-IV). Washington (DC), American Psychiatric Association, 1994.
2. Arcia E, Fernandez MC: Presenting problems and assigned diagnoses among young Latino children with disruptive behavior. J Atten Disord 6:177-185, 2003.
3. Arnold LE, Elliot M, Sachs L, Bird H, Kraemer HC, Wells KC, Abikoff HB, Comarda A, Conners CK, Elliott GR, Greenhill LL, Hechtman L, Hindshaw SP, Hoza B, Jensen PS, March JS, Newcorn JH, Pelham WE, Severe JB, Swanson JM, Vitiello B, Wigal T: Effects of ethnicity on treatment attendance, stimulant response/dose, and 14-month outcome in ADHD. J Consult Clin Psychol 71:713-727, 2003.
4. Bauermeister JJ, Canino G, Bravo M, Ramirez R, Jensen PS, Chavez L, Martinez-Taboas A, Ribera J, Alegria M, Garcia P: Stimulant and psychosocial treatment of ADHD in Latino/Hispanic children. J Am Acad Child Adolesc Psychiatry 42:851-855, 2003.
5. Bloom B, Tonthat L: Summary health statistics for US children: National Health Interview Survey, 1997. Vital Health Stat 10:1-46, 2002.
6. Canino G, Shrout PE, Rubio-Stipec M, Bird HR, Bravo M, Ramirez R, Chavez L, Alegria M, Bauermeister JJ, Hohmann A, Ribera J, Garcia P, Martinez-Taboas A: The DSM-IV rates of child and adolescent disorders in Puerto Rico: Prevalence, correlates, service use, and the effects of impairment. Arch Gen Psychiatry 61:85-93, 2004.
7. CEPAL: Statistical series for Latin America and the Caribbean. Part Two. pp 181-188, 2004. Accessed at http://www.eclac.cl/publicaciones/Estadisticas/4/ LCG2264PB/p2_1.pdf July 5, 2006.
8. Conners CK, Barkley RA: Rating scales and checklists for child psychopharmacology. Psychopharmacol Bull 21:839-943, 1985.
9. Conners CK, Sitarenios G, Parker JD, Epstein JN: The revised Conners' Parent Rating Scale (CPRS-R): Factor structure, reliability, and criterion validity. J Abnorm Child Psychol 26:257-268, 1998.
10. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R: ADHD Rating Scale-IV: Checklist, norms, and clinical interpretations. New York, The Guilford Press, 1998.
11. Escobar JI, Tuason VB: Antidepressant agents: A cross-cultural study. Psychopharmacol Bull 16:49-52, 1980.
12. Goldman LS, Genel M, Bezman RJ, Slanetz PJ: Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. JAMA 279:1100-1107, 1998.
13. Guy W: ECDEU assessment manual for psychopharmacology, revised. Bethesda (Maryland), US Department of Health, Education, and Welfare, 1976.
14. Isaza CA, Henao J, Lopez AM, Cacabelos R: Isolation, sequence and genotyping of the drug metabolizer CYP2D6 gene in the Colombian population. Methods Find Exp Clin Pharmacol 22:695-705, 2000.
15. Jensen PS, Kettle L, Roper MT, Sloan MT, Dulcan MK, Hoven C, Bird HR, Bauermeister JJ, Payne JD: Are stimulants overprescribed? Treatment of ADHD in four U.S. communities. J Am Acad Child Adolesc Psychiatry 38:797-804, 1999.
16. Jorge LF, Eichelbaum M, Griese EU, Inaba T, Arias TD: Comparative evolutionary pharmacogenetics of CYP2D6 in Ngawbe and Embera Amerindians of Panama and Colombia: Role of selection versus drift in world populations. Pharmacogenetics 9:217-228, 1999.
17. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Williamson D, Ryan N: Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): Initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36:980-988, 1997.
18. Marcos LR, Cancro R: Pharmacotherapy of Hispanic depressed patients: Clinical observations. Am J Psychother 36:505-512, 1982.
19. Mendoza R, Wan YJ, Poland RE, Smith M, Zheng Y, Berman N, Lin KM: CYP2D6 polymorphism in a Mexican American population. Clin Pharmacol Ther 70:552-560, 2001.
20. Pastor PN, Reuben CA: Racial and ethnic differences in ADHD and LD in young school-age children: Parental reports in the National Health Interview Survey. Public Health Rep 120:383-392, 2005.
21. Pineda DA, Lopera F, Henao GC, Palacio JD, Castellanos FX, Grupo de Investigación Fundema: Confirmation of the high prevalence of attention deficit disorder in a Colombian community. Rev Neurol 32:217-222, 2001. [Spanish]
22. Ring BJ, Gillespie JS, Eckstein JA, Wrighton SA: Identification of the human cytochromes P450 responsible for atomoxetine metabolism. Drug Metab Dispos 30:319-323, 2002.
23. Sánchez-Lacay JA, Lewis-Fernandez R, Goetz D, Blanco C, Salmán E, Davies S, Liebowitz M: Open trial of nefazodone among Hispanics with major depression: Efficacy, tolerability, and adherence issues. Depress Anxiety 13:118-124, 2001.
24. Stevens J, Harman JS, Kelleher KJ: Ethnic and regional differences in primary care visits for attention-deficit hyperactivity disorder. J Dev Behav Pediatr 25:318-325, 2004.
25. Versiani M, Ontiveros A, Mazzotti G, Ospina J, Dávila J, Mata S, Pacheco A, Plewes J, Tamura R, Palacios M: Fluoxetine versus amitriptyline in the treatment of major depression with associated anxiety (anxious depression): A double-blind comparison. Int Clin Psychopharmacol 14:321-327, 1999.
26. Wagner GJ, Maguen S, Rabkin JG: Ethnic differences in response to fluoxetine in a controlled trial with depressed HIV-positive patients. Psychiatr Serv 49:239-240, 1998.
27. Witcher JW, Long A, Smith B, Sauer JM, Heilgenstein J, Wilens T, Spencer T, Biederman J: Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 13:53-63, 2003.